September 3, 2021

The European Commission extends the approval of Ravulizumab-cwvz in paroxysmal nocturnal hemoglobinuria with paediatric indication

The European Commission has granted extended approval for the use of ravulizumab-cwvz in young people weighing at least 10 kg, as well as in adolescents with paroxysmal nocturnal haemoglobinuria.

The European Commission extends the approval of Ravulizumab-cwvz in paroxysmal nocturnal hemoglobinuria with paediatric indication Read More »